Vaccines for Lyme Borreliosis: Facts and Challenges

Bodnárová, S.; Čížková, D.; Hudáková, N.; Mangesh, Bhide M.

doi:10.2478/fv-2022-0006

Abstract

Lyme borreliosis (LB) is a multisystem infectious disease abundant in the northern countries of the world and is caused by Borrelia species. Vaccination against LB is an effective way to prevent and reduce the number of diseases in endemic areas. Several vaccines have been developed and tested in the past, but no human LB vaccine is currently available on the market. This review aims to uncover and delineate various strategies and diverse technological approaches related to vaccine production. Furthermore, we characterize already tested vaccines, possibilities for their future development, and reasons for their failure.

References

1. Adeolu, M., Gupta, R. S., 2014: A phylogenomic and molecular marker based proposal for the division of the genus Borrelia into two genera: the emended genus Borrelia containing only the members of the relapsing fever Borrelia, and the genus Borreliella gen. nov. containing the members of the Lyme disease Borrelia (Borrelia burgdorferi sensu lato complex). Antonie Van Leeuwenhoek, 105, 6, 1049—1072. DOI: 10.1007/s10482-014-0164-x.10.1007/s10482-014-0164-x24744012
Search in Google Scholar Back to article
2. Aronowitz, R. A., 2012: The rise and fall of the lyme disease vaccines: a cautionary tale for risk interventions in American medicine and public health. Milbank Q, 90, 2, 250—277. DOI: 10.1111/j.1468-0009.2012.00663.x.10.1111/j.1468-0009.2012.00663.x346020822709388
Search in Google Scholar Back to article
3. Bencurova, E., Gupta, S. K., Oskoueian, E., Bhide, M., Dandekar, T., 2018: Omics and bioinformatics applied to vaccine development against Borrelia. Mol. Omics., 14, 5, 330—340. DOI: 10.1039/c8mo00130h.10.1039/C8MO00130H
Search in Google Scholar Back to article
4. Bensaci, M., Bhattacharya, D., Clark, R., Linden, T. Hu., 2012: Oral vaccination with vaccinia virus expressing the tick antigen subolesin inhibits tick feeding and transmission of Borrelia burgdorferi vaccination. Vaccine, 30, 42, 6040—6046. DOI: 10.1016/j.vaccine.2012.07.053.10.1016/j.vaccine.2012.07.053393895422864146
Search in Google Scholar Back to article
5. Bins, A. D., Jorritsma, A., Wolkers, M. C., Hung, Ch. Fu., Wu, T. C., Schumacher, T. N. M., Haanen, J. B. A. G., 2005: A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med., 11, 8, 899—904. DOI: 10.1038/nm1264.10.1038/nm126415965482
Search in Google Scholar Back to article
6. Bunikis, J., Tsao, J., Luke, C. J., Luna, A. G., Fish, D., Barbour, A. G., 2004: Borrelia burgdorferi infection in a natural population of Peromyscus leucopus mice: a longitudinal study in an area where Lyme Borreliosis is highly endemic. J. Infect. Dis., 189, 8, 1515—1523. DOI: 10.1086/382594.10.1086/38259415073690
Search in Google Scholar Back to article
7. CDC 24/7: Saving Lives, Protecting PeopleTM: Notice to Readers Availability of Lyme Disease Vaccine. https://www.cdc.gov/mmwr/preview/mmwrhtml/00056299.htm. Updated January 22, 1999. Accesed February 19, 2021.
Search in Google Scholar Back to article
8. Comstedt, P., Hanner, M., Schüler. W., Meinke, A., Schlegl, R., Lundberg, U., 2015: Characterization and optimization of a novel vaccine for protection against Lyme borreliosis. Vaccine, 33, 44, 5982—5988. DOI: 10.1016/j. vaccine.2015.07.095.10.1016/j.vaccine.2015.07.095
Search in Google Scholar Back to article
9. Earnhart, C. G., Buckles, E. L., Marconi, R. T, 2006: Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine, 25, 3, 466—480. DOI: 10.1016/j.vaccine.2006.07.052.10.1016/j.vaccine.2006.07.05216996663
Search in Google Scholar Back to article
10. Earnhart, C. G., Marconi, R. T., 2007: Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens. Vaccine, 25, 17, 3419—3427. DOI: 10.1016/j. vaccine.2006.12.051.10.1016/j.vaccine.2006.12.051
Search in Google Scholar Back to article
11. Embers, M. E., Narasimhan, S., 2013: Vaccination against Lyme disease: past, present, and future. Front. Cell Infect. Microbiol., 3, 6. DOI: 10.3389/fcimb.2013.00006.10.3389/fcimb.2013.00006356983823407755
Search in Google Scholar Back to article
12. Federizon, J., Frye, A., Huang, W-C., Hart, T. M., He, X., Beltran, C., et al., 2020: Immunogenicity of the Lyme disease antigen OspA, particleized by cobalt porphyrin-phospholipid liposomes. Vaccine, 38, 4, 942—950. DOI: 10.1016/j.vaccine.2019.10.073.10.1016/j.vaccine.2019.10.073698077231727504
Search in Google Scholar Back to article
13. Fingerle, V., Schulte-Spechtel, U. C., Ruzic-Sabljic, E., Leonhard, S., Hofmann, H., Weber, K., et al., 2008: Epidemiological aspects and molecular characterization of Borrelia burgdorferi s. l. from southern Germany with special respect to the new species Borrelia spielmanii sp. nov. Int. J. Med. Microbiol., 2, 279—290. DOI: 10.1016/j.ijmm.2007.05.002.10.1016/j.ijmm.2007.05.00217616434
Search in Google Scholar Back to article
14. Gerritzen, M. J. H., Martens, D. E., Wijffels, R. H., Van der Pol, L., Stork, M., 2017: Bioengineering bacterial outer membrane vesicles as vaccine platform. Biotechnol. Adv., 35, 5, 565—574. DOI: 10.1016/j.biotechadv.2017.05.003.10.1016/j.biotechadv.2017.05.00328522212
Search in Google Scholar Back to article
15. Gomes-Solecki, M., Arnaboldi, P. M., Backenson, P. B., Benach, J. L., Cooper, C. L., Dattwyler, R. J., et al., 2020: Protective immunity and new vaccines for Lyme disease. Clin. Infect. Dis., 70, 8, 1768—1773. DOI: 10.1093/cid/ciz872.10.1093/cid/ciz872715578231620776
Search in Google Scholar Back to article
16. Gomes-Solecki, M. J. C., Brisson, D. R., Dattwyler, R. J., 2006: Oral vaccine that breaks the transmission cycle of the Lyme disease spirochete can be delivered via bait. Vaccine, 24, 20, 4440—4449: DOI: 10.1016/j.vaccine.2005.08.089.10.1016/j.vaccine.2005.08.08916198456
Search in Google Scholar Back to article
17. Hassan, W. S., Giaretta, P. R., Rech, R., Ollivault- Shiflett, M., Esteve-Gasent, M., 2019: Enhanced protective efficacy of Borrelia burgdorferi BB0172 derived-peptide based vaccine to control Lyme disease. Vaccine, 37, 5596—5606. DOI: 10.1016/j.vaccine.2019.07.092.10.1016/j.vaccine.2019.07.09231387750
Search in Google Scholar Back to article
18. Izac, J. R., O’Bier, N. S., Oliver, L. D., Camire, A. C., Earnhart, C. G., LeBlanc Rhodes, D. L. V., et al., 2020: Development and optimization of OspC chimeritope vaccinogens for Lyme disease. Vaccine, 38, 8,1915—1924. DOI: 10. 1016/j.vaccine.2020.01.027.10.1016/j.vaccine.2020.01.027708541031959423
Search in Google Scholar Back to article
19. Jan, A. T, 2017: Outer membrane vesicles (OMVs) of Gram-negative bacteria: A perspective update. Front. Microbiol., 8, 1053. DOI: 10.3389/fmicb.2017.01053.10.3389/fmicb.2017.01053546529228649237
Search in Google Scholar Back to article
20. Kamp, H. D., Swanson, K. A., Wei, R. R., Pradeep, K. D., Dharanipragada, R., Kern, A., Sharma, B., et al., 2020: Design of a broadly reactive Lyme disease vaccine. Npj. Vaccines, 5, 1, 1—10. DOI: 10.1038/s41541-020-0183-8.10.1038/s41541-020-0183-8719541232377398
Search in Google Scholar Back to article
21. Khatchikian, C. E., Nadelman, R. B., Nowakowski, J., Schwartz, I., Wormser, G. P., Brisson, D., 2014: Evidence for strain-specific immunity in patients treated for early Lyme disease. Infect. Immun., 82, 4, 1408—1411. DOI: 10.1128/IAI. 01451-13.10.1128/IAI.01451-13
Search in Google Scholar Back to article
22. Klouwens, M. J., Salverda, M. L. M., Trentelman, J. J., Ersoz, J. I., Wagemakers, A., Gerrizten, M. J., et al., 2021: Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis. Vaccine, 39,18, 2561—2567. DOI: 10.1016/j.vac cine.2021.03.059.10.1016/j.vaccine.2021.03.059
Search in Google Scholar Back to article
23. Klouwens, M. J., Trentelman, J. J., Ersoz, J. I., Nieves Marques Porto, F., Sima, R., Hajdusek, O., et al., 2021: Investigating BB0405 as a novel Borrelia afzelii vaccination candidate in Lyme borreliosis. Sci. Rep., 11, 1, 4775. DOI: 10.1038/s41598-021-84130-y.10.1038/s41598-021-84130-y791057333637813
Search in Google Scholar Back to article
24. Klouwens, M. J., Trentelman, J. J. A., Wagemakers, A., Ersoz, J. I., Bins, A. D., Hovius, J. W., 2021: Tick-tattoo: DNA vaccination against B. burgdorferi or Ixodes scapularis tick proteins. Front. Immunol., 12, 615011. DOI: 10.3389/fim mu.2021.615011.10.3389/fimmu.2021.615011
Search in Google Scholar Back to article
25. Kuleš, J., Horvatić, A., Guillemin, N., Galan, A., Mrljak, V., Bhide, M., 2016: New approaches and omics tools for mining of vaccine candidates against vector-borne diseases. Mol. Biosyst., 12, 9, 2680—2694. DOI: 10.1039/C6MB00 268D.10.1039/C6MB00268D
Search in Google Scholar Back to article
26. Kumar, M., Kaur, S., Kariu, T., Yang, X., Bossis, I., Anderson, J. F., et al., 2011: Borrelia burgdorferi BBA52 is a potential target for transmission blocking Lyme disease vaccine. Vaccine, 29, 48, 9012—9019, DOI: 10.1016/j.vaccine. 2011.09.035.10.1016/j.vaccine.2011.09.035
Search in Google Scholar Back to article
27. Kung, F., Kaur, S., Smith, A. A.,Yang, X., Wilder, C. N., Sharma, K., et al., 2016: A Borrelia burgdorferi surface-exposed transmembrane protein lacking detectable immune responses supports pathogen persistence and constitutes a vaccine target. J. Infect. Dis., 213, 11, 1786—1795. DOI: 10.1093/infdis/jiw013.10.1093/infdis/jiw013485746826747708
Search in Google Scholar Back to article
28. Kutzler, M. A., Weiner, D. B., 2008: DNA vaccines: ready for prime time ? Nat. Rev. Genet., 9, 10, 776—788. DOI: 10. 1038/nrg2432.10.1038/nrg2432431729418781156
Search in Google Scholar Back to article
29. LaFleur, R. L., Callister, S. M., Dant, J. C., Jobe, D. A., Lovrich, S. D., Warner, T. F., et al., 2010: One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin. Clin. Vaccine Immunol., 17, 5, 870—874. DOI: 10. 1128/CVI.00524-09.10.1128/CVI.00524-09286339720237200
Search in Google Scholar Back to article
30. LaFleur, R. L., Dant, J. C., Wasmoen, T. L., Callister, S. M., Jobe, D. A., Lovrich, S., D., et al., 2009: Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin. Vaccine Immunol., 16, 2, 253—259. DOI: 10. 1128/CVI.00373-08.10.1128/CVI.00373-08264353419052162
Search in Google Scholar Back to article
31. Levy, S. A., 2002: Use of a C6 ELISA test to evaluate the efficacy of a whole-cell bacterin for the prevention of naturally transmitted canine Borrelia burgdorferi infection. Vet. Ther. Res. Appl. Vet. Med., 3, 4, 420—424.32.
Search in Google Scholar Back to article
32. Levy, S. A., Millership, J., Glover, S., Parker, D., Hogan, J., Heldorfer, M., et al., 2010: Confirmation of presence of Borrelia burgdorferi outer surface protein C antigen and production of antibodies to Borrelia burgdorferi outer surface protein C in dogs vaccinated with a whole-cell Borrelia burgdorferi bacterin. Intern. J. Appl Vet. Med., 8, 3, 123—128.
Search in Google Scholar Back to article
33. Little, S. E., Heise, S. R., Blagburn, B. L., Callister, S. M., Mead, P. S., 2010: Lyme borreliosis in dogs and humans in the USA. Trends Parasitol., 26, 4, 213–—218. DOI: 10.1016/j.pt.2010.01.006.10.1016/j.pt.2010.01.00620207198
Search in Google Scholar Back to article
34. Mancini, F., Rossi, O., Necchi, F., Micholi, F., 2020: OMV vaccines and the role of TLR agonists in immune response. Int. J. Mol. Sci., 21, 12, 4416. DOI: 10.3390/ijms21124416.10.3390/ijms21124416735223032575921
Search in Google Scholar Back to article
35. Marconi, R. T., Garcia-Tapia, D., Hoevers, J., Honsberger, N., King, V. L., Ritter, D., et al., 2020: VANGUARD®cr-Lyme: A next generation Lyme disease vaccine that prevents B. burgdorferi infection in dogs. Vaccine X, 6, 11, 100079. DOI: 10.1016/j.jvacx.2020.100079.10.1016/j.jvacx.2020.100079773314433336185
Search in Google Scholar Back to article
36. Meirelles Richer, L., Aroso, M., Contente-Cuomo, T., Ivanova, L., Gomes-Solecki, M., 2011: Reservoir targeted vaccine for Lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice. Clin. Vaccine Immunol., CVI, 11, 18, 1809—1816. DOI: 10.1128/CVI.05226-11.10.1128/CVI.05226-11320901221918116
Search in Google Scholar Back to article
37. Murfin, K. E., Fikrig, E., 2017: Tick bioactive molecules as novel therapeutics: Beyond vaccine targets. Front. Cell Infect. Microbiol., 7, 222. DOI: 10.3389/fcimb.2017.00222.10.3389/fcimb.2017.00222545989228634573
Search in Google Scholar Back to article
38. Nadelman, R. B., Wormser G. P., 1998: Lyme borreliosis. Lancet, 352, 9127, 557—565. DOI: 10.1016/S0140-6736 (98)01146-5.10.1016/S0140-6736(98)01146-5
Search in Google Scholar Back to article
39. Nardelli, D. T., Munson, E. L., Callister, S. M., Schell, R., 2009: Human Lyme disease vaccines: past and future concerns. Future Microbiol., 4, 4, 457—469. DOI: 10.2217/fmb. 09.17.10.2217/fmb.09.17
Search in Google Scholar Back to article
40. Nayak, A., Schüler, W., Seidel, S., Gomez, I., Meinke, A., Comstedt, P., et al., 2020: Broadly protective multivalent OspA vaccine against Lyme borreliosis, developed based on surface shaping of the C-terminal fragment. Infect Immun., 88, 4. DOI: 10.1128/IAI.00917-19.10.1128/IAI.00917-19709314131932330
Search in Google Scholar Back to article
41. Nelson, C. A., Saha, S., Kugeler, K. J., Delorey, M. J., Shankar, M. B., Hinckley, A. F., et al., 2015: Incidence of clinician-diagnosed Lyme disease, United States, 2005—2010. Emerg. Infect. Dis., 21, 9, 1625—1631. DOI: 10.3201/eid2109.150417.10.3201/eid2109.150417455014726291194
Search in Google Scholar Back to article
42. Nigrovic, L. E., Thompson, K. M., 2007: The Lyme vaccine: a cautionary tale. Epidemiol. Infect., 135, 1, 1—8. DOI: 10. 1017/S0950268806007096.10.1017/S0950268806007096287055716893489
Search in Google Scholar Back to article
43. Pereira, V. B., Zurita-Turk, M., Saraiva, T. D. L., De Castro, C. P., Souza, B. M., Agresti, P. M., et al., 2014: DNA vaccines approach: From concepts to applications. World J. Vaccines, 4, 2, 50—71. DOI: 10.4236/wjv.2014.42008.10.4236/wjv.2014.42008
Search in Google Scholar Back to article
44. Plotkin, S. A., 2016: Need for a new Lyme disease vaccine. N. Engl. J. Med., 375, 10, 911—913. DOI: 10.1056/NEJMp 1607146.10.1056/NEJMp1607146
Search in Google Scholar Back to article
45. Pol van der, L., Stork, M., Ley van der, P., 2015: Outer membrane vesicles as platform vaccine technology. Biotechnol. J., 10, 11, 1689—1706. DOI: 10.1002/biot.201400395.10.1002/biot.201400395476864626912077
Search in Google Scholar Back to article
46. Poland, G. A., 2011: Vaccines against Lyme disease: What happened and what lessons can we learn ? Clin. Infect. Dis., 52, 253—258. DOI: 10.1093/cid/ciq116.10.1093/cid/ciq11621217172
Search in Google Scholar Back to article
47. Radolf, J. D., Caimano, M. J., Stevenson, B., Hu, L. T., 2012: Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat. Rev. Microbiol., 10, 2, 87—99. DOI: 10.1038/nrmicro2714.10.1038/nrmicro2714331346222230951
Search in Google Scholar Back to article
48. Rizzoli, A., Hauffe, H. C., Carpi, G., Vourc’h, G. I., Neteler, M., Rosa, R., 2011: Lyme borreliosis in Europe. Eurosurveillance, 16, 27, 19906, 1—8. DOI: 10.2807/ese.16.27. 19906-en.10.2807/ese.16.27.19906-en
Search in Google Scholar Back to article
49. RxList, 2016: Side Effects of Lymerix (Lipoprotein Outer Surface A Vaccine), Warnings, Uses. RxList. https://www.rx-list.com/lymerix-side-effects-drug-center.htm. Last reviewed on RxList April 29, 2016. Accessed February 19, 2021.
Search in Google Scholar Back to article
50. Scheckelhoff, M. R., Telford, S. R., Hu, L. T., 2006: Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine, 24, 11, 1949—1957. DOI: 10.1016/j.vaccine. 2005.10.044.10.1016/j.vaccine.2005.10.044
Search in Google Scholar Back to article
51. Schuijt, T. J., Hovius, J. W., Poll van der, T., Dam van, A. P., Fikrig, E., 2011: Lyme borreliosis vaccination: the facts, the challenge, the future. Trends Parasitol., 27, 1, 40—47. DOI: 10.1016/j.pt.2010.06.006.10.1016/j.pt.2010.06.00620594913
Search in Google Scholar Back to article
52. Seinost, G., Golde, W. T., Berger, B. W., Dunn, J. J., Qiu, D., Dunkin, D. S., et al., 1999: Infection with multiple strains of Borrelia burgdorferi sensu stricto in patients with Lyme disease. Arch. Dermatol., 135, 11, 1329—1333. DOI: 10.1001/archderm.135.11.1329.10.1001/archderm.135.11.132910566830
Search in Google Scholar Back to article
53. Sigal, L. H., Zahradnik, J. M., Lavin, P., Patella, S. J., Bryant, G., Haselby, R., et al., 1998: A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant outer-surface protein A Lyme disease. N. Engl. J. Med., 339, 4, 216—222. DOI: 10.1056/NEJM199807233390402.10.1056/NEJM1998072333904029673299
Search in Google Scholar Back to article
54. Šmit, R., Postma, M. J., 2015: Lyme borreliosis: reviewing potential vaccines, clinical aspects and health economics. Expert. Rev. Vaccines, 14, 12, 1549—1561. DOI: 10.1586/1476 0584.2015.1091313.10.1586/14760584.2015.1091313
Search in Google Scholar Back to article
55. Stanek, G., Wormser, G., Gray, J., Strle, F., 2012: Lyme borreliosis. Lancet, 379, 9814, 461—473. DOI: 10.1016/S01 40-6736(11)60103-7.10.1016/S0140-6736(11)60103-7
Search in Google Scholar Back to article
56. Steere, A. C., Sikand, V. K., Meurice, F. Parenti, D. L., Fikrig, E., Schoen, R. T., et al., 1998: Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med., 339, 4, 209—215. DOI: 10. 1056/NEJM199807233390401.10.1056/NEJM1998072333904019673298
Search in Google Scholar Back to article
57. Steere, A. C., Strle. F., Wormser, G. P., Hu, L. T., Branda, J. A., Hovius, J. W. R., et al., 2016: Lyme borreliosis. Nat. Rev. Dis. Primer, 2, 16090. DOI: 10.1038/nrdp.2016.90.10.1038/nrdp.2016.90553953927976670
Search in Google Scholar Back to article
58. Sykes, R. A., Makiello, P., 2017: An estimate of Lyme borreliosis incidence in western Europe. J. Public Health Oxf. Engl., 39, 1, 74—81. DOI: 10.1093/pubmed/fdw017.10.1093/pubmed/fdw01726966194
Search in Google Scholar Back to article
59. Todaro, W. T., Schoen, R. T., 2000: The Lyme disease vaccine: Conception, development, and implementation. Ann. Intern. Med., 132, 8, 661—668.10.7326/0003-4819-132-8-200004180-0000910766685
Search in Google Scholar Back to article
60. Töpfer, K. H., Straubinger, R. K., 2007: Characterization of the humoral immune response in dogs after vaccination against the Lyme borreliosis agent: A study with five commercial vaccines using two different vaccination schedules. Vaccine, 25, 2, 314—326. DOI: 10.1016/j.vaccine.2006.07.031.10.1016/j.vaccine.2006.07.03116930782
Search in Google Scholar Back to article
61. Valneva, 2020: Valneva Announces Acceleration of Pediatric Development for Lyme Disease Vaccine Candidate—Valneva. https://valneva.com/press-release/valneva-announces-acceleration-of-pediatric-development-for-lyme-disease-vaccine-candidate/. Updated December 2, 2020. Accessed February 4, 2021
Search in Google Scholar Back to article
62. Valneva, 2021: Valneva Announces Positive Initial Results for Phase 2 Study of Lyme Disease Vaccine Candidate—Valneva. https://valneva.com/press-release/valneva-announces-positive-initial-results-for-phase-2-study-of-lyme-disease-vaccine-candidate/. Updated July 22, 2020. Accessed February 4, 2021.
Search in Google Scholar Back to article
63. Valneva, 2021: Valneva Announces Positive Initial Results for Second Phase 2 Study of Lyme Disease Vaccine Candidate VLA15—Valneva. https://valneva.com/press-release/valneva-announces-positive-initial-results-for-second-phase-2-study-of-lyme-disease-vaccine-candidate-vla15/. Updated October 20, 2020. Accessed February 4, 2021.
Search in Google Scholar Back to article
64. Wagemakers, A., Mason, L. M. K., Oei, A., Wever de, B., Poll van der, T., Bins, A. D., et al., 2014: Rapid outer-surface protein C DNA tattoo vaccination protects against Borrelia afzelii infection. Gene Ther., 21, 1051—1057. DOI: 10. 1038/gt.2014.87.10.1038/gt.2014.8725273355
Search in Google Scholar Back to article
65. We Respect Animals—Bioveta, 2015: Borrelym 3—new unique vaccine. https://www.bioveta.eu/en/news/news-in-assortment/borrelym-3-new-unique-vaccine.html: Updated March 3, 2015. Accesssed March 15, 2020.
Search in Google Scholar Back to article

Vaccines for Lyme Borreliosis: Facts and Challenges

Abstract

Paradigm

My account